Mundipharma Satisfies Appetite For Piece Of $4.5bn Pegfilgrastim Pie With Cinfa Biotech Buy

Mundipharma widens its biosimilar portfolio by acquiring Cinfa Biotech, and its soon-to-be-launched pegfilgrastim biosimilar.

Apple pie
• Source: shutter stock

UK-based Mundipharma International Corp. Ltd. has added to its biosimilar basket with the acquisition of Cinfa Biotech, and with it, immediate access to revenues from the recently-approved Pelmeg, a biosimilar to Amgen Inc.’s neutropenia therapy Neulasta (pegfilgrastim).

While the terms of the deal were undisclosed, Mundipharma estimates the global market for Pelmeg to be up to $4

More from Deals

More from Business